YM reports nimotuzumab data in gastric cancer
YM BioSciences Inc. (TSX:YM; NYSE-A:YMI) reported preliminary data from a Phase II trial of nimotuzumab in patients with advanced or recurrent gastric cancer who are refractory to a 5-fluorouracil (5-FU)-containing regimen. The mAb against EGFR plus IV irinotecan led to worse median progression-free survival (PFS), the primary endpoint, vs. irinotecan alone at a median follow-up of 197 days (73 vs. 85 days). Median overall survival for nimotuzumab plus irinotecan was 293 days vs. 227 days for irinotecan alone. ...